Positive and Negative Roles of IL-6, STAT3, and SOCS3 in Inflammatory Arthritis

  • Ichiko Kinjyo
  • Masanobu Ohishi
  • Takanori Shouda
  • Takashi Kobayashi
  • Akihiko Yoshimura
Part of the Advances in Experimental Medicine and Biology book series (volume 602)

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of multiple joints, resulting in mononuclear cell infiltration, development of pannus, progressive cartilage destruction and bone erosion. Although the cause of RA remains unknown, it has been suggested that cytokines, especially proinflammatory cytokines such as tumor necrosis factor α(TNF-α), interleukin (IL)-1, and IL-6 derived from activated synovial cells, play a pivotal role in the pathology of the disease (Feldmann, Brennan, and Maini 1996a,b). Among these cytokines, TNF-α has been most extensively investigated as a target in the efforts to treat RA. Anti-TNF-α mAbs markedly ameliorate joint involvement in the majority of patients with RA (Elliott, Maini, Feldmann, et al. 1994a,b). It is well known that IL-6 is one of a major target gene of TNF-α. IL-6 has been proposed to contribute to the development of arthritis; IL-6 induces proliferation of synovial fibroblastic cells (Mihara, Moriya, Kishimoto, et al. 1995) and formation of osteoclasts, in association with soluble IL-6 receptors (Tamura, Udagawa, Takahashi, et al. 1993). Involvement of IL-6 in RA is also suggested by recent reports of IL-6-gene-disrupted mice that were resistant to antigen-induced arthritis (AIA) (Boe, Baiocchi, Carbonatto, et al. 1999; Ohshima, Saeki, Mima, et al. 1998) and collagen-induced arthritis (CIA) (Alonzi, Fattori, Lazzaro, et al. 1998). Therefore, IL-6 could be another therapeutic target of RA. Recently, anti-IL6 receptor antibodies have been successfully trialed as a therapy for RA patients (Yoshizaki, Nishimoto, Mihara, et al. 1998). However, the mechanism of suppression of RA by anti-IL-6 therapy has not been fully understood. We investigated the role of IL-6 and its signal regulator, SOCS3 on inflammatory arthritis and osteoclastgenesis using mouse models.


Leukemia Inhibitory Factor Osteoclast Differentiation Synovial Fibroblast Rheumatoid Arthritis Synovial Fibroblast Th17 Induction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Feldmann, M., F.M. Brennan, and R.N. Maini. 1996a. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397–440.CrossRefPubMedGoogle Scholar
  2. 2.
    Feldmann, M., F.M. Brennan, and R.N. Maini. 1996b. Rheumatoid arthritis. Cell 85(3): 307–310.CrossRefPubMedGoogle Scholar
  3. 3.
    Elliott, M.J., R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane, H. Biji, et al. 1994. Randomiced double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (8930): 1105–1110.CrossRefPubMedGoogle Scholar
  4. 4.
    Elliott, M.J., R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, H. Biji, and J.N. Woody. 1994. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344(8930): 1125–1127.CrossRefPubMedGoogle Scholar
  5. 5.
    Mihara, M., Y. Moriya, T. Kishimoto, and Y. Ohsugi. 1995. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 34(4): 321–325.CrossRefPubMedGoogle Scholar
  6. 6.
    Tamura, T., N. Udagawa, N. Takahashi, C. Miyaura, S. Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki, T. Taga, et al. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90(24): 11924–11928.CrossRefPubMedGoogle Scholar
  7. 7.
    Boe, A., M. Baiocchi, M. Carbonatto, R. Papoian, and O. Serlupi-Crescenzi. 1999. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11(12): 1057–1064.CrossRefPubMedGoogle Scholar
  8. 8.
    Ohshima, S., Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, et al. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95(14): 8222–8226.CrossRefPubMedGoogle Scholar
  9. 9.
    Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187(4): 461–468.CrossRefPubMedGoogle Scholar
  10. 10.
    Yoshizaki, K., N. Nishimoto, M. Mihara, and T. Kishimoto. 1998. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Serum Immunopathol 20(1–2): 247–259.CrossRefGoogle Scholar
  11. 11.
    Shouda, T., T. Yoshida, T. Hanada, T. Wakioka, M. Oishi, K. Miyoshi, S. Komiya, K. Kosai, Y. Hanakawa, K. Hashimoto, K. Nagata, and A. Yoshimura. 2001. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 108(12): 1781–1788.PubMedGoogle Scholar
  12. 12.
    Atsumi, T., et al. 2002. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 196(7): 979–990.CrossRefPubMedGoogle Scholar
  13. 13.
    Hirano, T., K. Ishihara, M. Hibi. 2000. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.Oncogene 19(21): 2548–2556.CrossRefPubMedGoogle Scholar
  14. 14.
    Xu, Q., J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G.L. Semenza, J.Q. Cheng, R. Jove, and H. Yu. 2005. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.Oncogene 24(36): 5552–5560.CrossRefPubMedGoogle Scholar
  15. 15.
    Ogata, H., T. Chinen, T. Yoshida, I. Kinjyo, G. Takaesu, H. Shiraishi, M. Iida, T. Kobayashi, A. Yoshimura. 2006. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 25(17): 2520–2530.CrossRefPubMedGoogle Scholar
  16. 16.
    O’Brien, C.A., et al. 1999. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274(27): 19301–19308.CrossRefPubMedGoogle Scholar
  17. 17.
    Kubo, M., T. Hanada, and A. Yoshimura. 2003. Suppressors of cytokine signaling and immunity. Nat Immunol 4(12): 1169–1176.CrossRefPubMedGoogle Scholar
  18. 18.
    Yoshimura, A., H. Nishinakamura, Y. Matsumura, and T. Hanada. 2005. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 7(3): 100–110.CrossRefPubMedGoogle Scholar
  19. 19.
    Takeda, K., et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10(1): 39–49.CrossRefPubMedGoogle Scholar
  20. 20.
    Yasukawa, H., et al. 2003. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4(6): 551–556.CrossRefPubMedGoogle Scholar
  21. 21.
    Lang, R., et al. 2003. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4(6): 546–550.CrossRefPubMedGoogle Scholar
  22. 22.
    Croker, B.A., et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4(6): 540–545.CrossRefPubMedGoogle Scholar
  23. 23.
    Hayashi, T., T. Kaneda, Y. Toyama, M. Kumegawa, and Y. Hakeda. 2002. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem 277(31): 27880–27886.CrossRefPubMedGoogle Scholar
  24. 24.
    Clausen, B.E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Forster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8(4): 265.CrossRefPubMedGoogle Scholar
  25. 25.
    Ohishi, M., Y. Matsumura, D. Aki, R. Mashima, K. Taniguchi, T. Kobayashi, T. Kukita, Y. Iwamoto, and A. Yoshimura. 2005. Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines. J Immunol 174(5): 3024–3031.PubMedGoogle Scholar
  26. 26.
    Takayanagi, H., K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokochi, H. Oda, K. Tanaka, K. Nakamura, and T. Taniguchi. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408(6812): 600–605.CrossRefPubMedGoogle Scholar
  27. 27.
    Seki, Y., H. Inoue, N. Nagata, K. Hayashi, S. Fukuyama, K. Matsumoto, O. Komine, S. Hamano, K. Himeno, K. Inagaki-Ohara, N. Cacalano, A. O’Garra, T. Oshida, H. Saito, J.A. Johnston, A. Yoshimura, and M. Kubo. 2003. SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses. Nat Med 9(8): 1047–1054.CrossRefPubMedGoogle Scholar
  28. 28.
    Kinjyo, I., H. Inoue, S. Hamano, S. Fukuyama, T. Yoshimura, K. Koga, H. Takaki, K. Himeno, G. Takaesu, T. Kobayashi, and A. Yoshimura. 2006. Related Articles, Links Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 203(4): 1021–1031.CrossRefPubMedGoogle Scholar
  29. 29.
    Chen, Z., A. Laurence, Y. Kanno, M. Pacher-Zavisin, B.M. Zhu, C. Tato, A. Yoshimura, L. Hennighausen, and J.J. O’Shea. 2006. Related Articles, Links Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103(21): 8137–8142.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Ichiko Kinjyo
    • 1
  • Masanobu Ohishi
    • 1
  • Takanori Shouda
    • 1
  • Takashi Kobayashi
    • 1
  • Akihiko Yoshimura
    • 1
  1. 1.Division of Molecular and Cellular ImmunologyKyushu UniversityHigashi-kuJapan

Personalised recommendations